A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
West Springfield, 1090, Austria
Federal District, 72115700, Belgium
Plainfield, 1070, Belgium
Tianjin, Hebei 300060, China
Englewood, 34295, France
Marseil, 13285, France
Abeno-ku, Osaka 545-8586, Japan
Izunokuni-Shi, Shizuoka 4102295, Japan
Minato-ku, Tokyo 105-8470, Japan
Minato-ku, Tokyo 105-8470, Japan
Musashino-shi, Tokyo 180-8610, Japan
Gyeongsangnam-do, 050612, South Korea
Hwasun-Gun, 58128, South Korea
Tapei, 11217, Taiwan